Abbisko Therapeutics
↗Shanghai, China
Abbisko Therapeutics is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. Founded in 2016 by a team of industry veterans, the company focuses on precision oncology and immuno-oncology, leveraging an in-house R&D engine to address critical unmet medical needs globally.
The company has built a robust pipeline of over 10 small molecule programs, with multiple assets in clinical development. Abbisko has established strategic partnerships with multinational pharmaceutical companies, including a significant licensing agreement with Merck for its lead asset, pimicotinib (ABSK021), a CSF-1R inhibitor currently in late-stage clinical trials for Tenosynovial Giant Cell Tumor (TGCT).
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Founded:2016
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$263M
Investors:Temasek, The Carlyle Group, TF Capital, Lilly Asia Venture, Qiming Venture Partners
STOCK
Exchange:Hong Kong Stock Exchange (HKEX)
Ticker:2256
Market Cap:$1.15B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Small molecule
Active Trials:5
Trial Phases:Phase 1: 2 | Phase 2: 2 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Merck (Global commercialization for pimicotinib), X4 Pharmaceuticals
COMPETITION
Position:Emerging
Competitors:Enliven Therapeutics, Q32 Bio, Nuvalent, Lepu Biopharma
LEADERSHIP
Key Executives:
Yao-chang Xu - Chairman
LINKS
Website:abbisko.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Abbisko Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Abbisko Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.